Patent application EP20179945A (EP), filed 2020-06-15
Publication number: EP3756651A1
Title: OPHTHALMIC PRODUCT WITH CORNEA REPAIR FUNCTION
Abstract: An ophthalmic product (300, 400) having a cornea repair function includes an ophthalmic composition. The ophthalmic composition includes gold nanoparticles (100) serving as the main repairing ingredient and at least one auxiliary repairing ingredient. An effective concentration of the gold nanoparticles (100) is from 0.01 ppm to 3000 ppm. The content of the at least one auxiliary repairing ingredient is greater than 0 wt % and less than 20 wt % based on 100 wt % of the ophthalmic composition.
IPC codes: A61K  33/    24            A I
A61K  47/    12            A I
A61K  47/    18            A I
A61K  47/    20            A I
A61K  47/    36            A I
A61K  47/    50            A I
A61K   9/    00            A I
A61K   9/    08            A I
A61K   9/    14            A I
Claims: number: 1
text: An ophthalmic product (300, 400) having a cornea repair function characterized by comprising an ophthalmic composition that includes gold nanoparticles (100) and at least one auxiliary repairing ingredient, wherein an effective concentration of the gold nanoparticles (100) is from 0.01 ppm to 3000 ppm, and the content of the at least one auxiliary repairing ingredient is greater than 0 wt % and less than 20 wt % based on 100 wt % of the ophthalmic composition.
number: 2
text: The ophthalmic product (300, 400) according to claim 1, wherein the average particle size of the gold nanoparticles (100) is from 0.5 nm to 40 nm, the effective concentration of the gold nanoparticles (100) is from 1 ppm to 400 ppm, and the content of the at least one auxiliary repairing ingredient is from 0.05 wt % to 3 wt %.
number: 3
text: The ophthalmic product (300, 400) according to claim 1, wherein the gold nanoparticles (100) are each surface-modified with at least one functional molecular group that is selected from hydrophilic functional groups, phenol group-containing compounds, polysaccharide substances, peptide substances with at least one NH2 or COOH group and thiol ligands.
number: 4
text: The ophthalmic product (300, 400) according to claim 3, wherein the content of the at least one functional molecular group is from 0.01 wt % to 5 wt % based on 100 wt % of the ophthalmic composition.
number: 5
text: The ophthalmic product (300, 400) according to claim 3, wherein the hydrophilic functional groups include OH group, CONH group, CONH2 group and COOH group.
number: 6
text: The ophthalmic product (300, 400) according to claim 3, wherein the phenol group-containing compounds include monophenol, polyphenol and flavonoid compounds.
number: 7
text: The ophthalmic product (300, 400) according to claim 3, wherein the polysaccharide substances include uronic acids, methyl carboxylic acid chitin, methyl carboxylic acid chitosan, alginic acid and hyaluronic acid.
number: 8
text: The ophthalmic product (300, 400) according to claim 3, wherein the peptide substances have a molecular weight from 300 Daltons to 300,000 Daltons.
number: 9
text: The ophthalmic product (300, 400) according to claim 3, wherein the thiol ligands include lipoic acid and dihydrolipoic acid.
number: 10
text: The ophthalmic product (300, 400) according to claim 1, wherein the at least one auxiliary repairing ingredient is selected from chondroitin sulfate, α-lipoic acid, 2-aminoethanesulfonic acid and potassium L-aspartate.
number: 11
text: An ophthalmic product (300, 400) having a cornea repair function characterized by comprising an ophthalmic composition that includes gold nanoparticles (100), wherein an effective concentration of the gold nanoparticles (100) is from 0.01 ppm to 3000 ppm, and the average particle size of the gold nanoparticles (100) is from 0.01 nm to 100 nm.
number: 12
text: The ophthalmic product (300, 400) according to claim 11, wherein the average particle size of the gold nanoparticles (100) is from 0.5 nm to 40 nm.
number: 13
text: The ophthalmic product (300, 400) according to claim 11, wherein the effective concentration of the gold nanoparticles (100) is from 1 ppm to 400 ppm.
Office action: search_report, dated 2020-12-30
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: - THE INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017
ref_type: npl
severity: background
ref_id: CN109718376A
ref_type: patent
severity: background
ref_id: US2019175753A1
ref_type: patent
severity: background
ref_id: US2010028559A1
ref_type: patent
severity: background
ref_id: WO2020147830A1
ref_type: patent
severity: background
ref_id: - G. CHIDLOW ET AL: "[alpha]-lipoic acid protects the retina against ischemia-reperfusion", NEUROPHARMACOLOGY, vol. 43, no. 6, 1 November 2002 (2002-11-01), pages 1015 - 1025, XP055116278, ISSN: 0028-3908, DOI: 10.1016/S0028-3908(02)00129-6
ref_type: npl
severity: background
ref_id: - ANDRADE ALEXEY S ET AL: "Alpha-lipoic acid restores tear production in an animal model of dry eye", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, vol. 120, 4 January 2014 (2014-01-04), pages 1 - 9, XP028621785, ISSN: 0014-4835, DOI: 10.1016/J.EXER.2013.12.014
ref_type: npl
severity: background
ref_id: - SEBASTIAN FUNKE ET AL: "Longitudinal analysis of taurine induced effects on the tear proteome of contact lens wearers and dry eye patients using a RP-RP-Capillary-HPLC MALDI TOF/TOF MS approach", JOURNAL OF PROTEOMICS, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 11, 12 March 2012 (2012-03-12), pages 3177 - 3190, XP028511847, ISSN: 1874-3919, [retrieved on 20120324], DOI: 10.1016/J.JPROT.2012.03.018
ref_type: npl
severity: background
ref_id: - SANDRI GIUSEPPINA ET AL: "Platelet lysate and chondroitin sulfate loaded contact lenses to heal corneal lesions", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 509, no. 1, 24 May 2016 (2016-05-24), pages 188 - 196, XP029623680, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2016.05.045
ref_type: npl
severity: background
ref_id: US2010028559
ref_type: patent
severity: novelty_destroying
ref_id: CN109718376
ref_type: patent
severity: novelty_destroying
ref_id: US2019175753
ref_type: patent
severity: novelty_destroying
ref_id: WO2020147830
ref_type: patent
severity: novelty_destroying
Final disposition: pending (2020-12-30)